Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Neurocrine Bioscienc (NBIX)

Neurocrine Bioscienc (NBIX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Neurocrine Bioscienc 12780 EL CAMINO REAL SAN DIEGO CA 92130 USA

www.neurocrine.com P: 858-617-7600

Description:

Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The company's neuroscience, endocrine and immunology disciplines provide a unique biological understanding of the molecular interaction between central nervous, immune and endocrine systems for the development of therapeutic interventions for anxiety, depression, insomnia, stroke, malignant brain tumors, multiple sclerosis, obesity and diabetes.

Key Statistics

Overview:

Market Capitalization, $K 13,708,084
Enterprise Value, $K 13,456,984
Shares Outstanding, K 99,507
Annual Sales, $ 1,887 M
Annual Net Income, $ 249,700 K
Last Quarter Sales, $ 515,200 K
Last Quarter Net Income, $ 147,700 K
EBIT, $ 250,900 K
EBITDA, $ 254,600 K
60-Month Beta 0.25
% of Insider Shareholders 4.40%
% of Institutional Shareholders 92.59%
Float, K 95,129
% Float 95.60%
Short Volume Ratio 0.44

Growth:

1-Year Return 32.41%
3-Year Return 45.79%
5-Year Return 74.45%
5-Year Revenue Growth 318.20%
5-Year Earnings Growth 1,022.73%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 1.44 on 02/07/24
Latest Earnings Date 05/01/24 [BMO]
Earnings Per Share ttm 2.42
EPS Growth vs. Prev Qtr 75.61%
EPS Growth vs. Prev Year 63.64%
Annual Dividend Yield 0.00%
Dividend Payable Date 12/31/69
Dividend Payout Ratio 0.00%

NBIX Ratios

Ratio
Price/Earnings ttm 57.43
Price/Earnings forward 28.96
Price/Earnings to Growth N/A
Return-on-Equity % 12.85%
Return-on-Assets % 9.02%
Profit Margin % 13.23%
Debt/Equity 0.00
Price/Sales 7.33
Price/Cash Flow 54.32
Price/Book 6.17
Book Value/Share 22.72
Interest Coverage 73.20
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar